A Phase Ib ,Single Center, Open-labeling, Multiple Oral Dose Study to Assess the Safety, Tolerability PK and Efficacy Profile for Advanced Solid Tumor Patients in China

Trial Profile

A Phase Ib ,Single Center, Open-labeling, Multiple Oral Dose Study to Assess the Safety, Tolerability PK and Efficacy Profile for Advanced Solid Tumor Patients in China

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Icaritin (Primary)
  • Indications Advanced breast cancer; Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top